

Schriften aus dem Institut für Medizinische Mikrobiologie des  
Klinikums der Johann Wolfgang Goethe-Universität Frankfurt am Main

Band 2

**Klaus-Peter Hunfeld**

**Contributions to Seroepidemiology,  
Diagnosis, and Antimicrobial Susceptibility of  
*Borrelia, Ehrlichia, and Babesia* as  
Indigenous Tick-conducted Pathogens**

Shaker Verlag  
Aachen 2004

**Bibliographic information published by Die Deutsche Bibliothek**

Die Deutsche Bibliothek lists this publication in the Deutsche  
Nationalbibliografie; detailed bibliographic data is available in the internet at  
<http://dnb.ddb.de>.

Priv.-Doz. Dr. med. Klaus-Peter Hunfeld  
Institut für Medizinische Mikrobiologie  
Universitätsklinikum Frankfurt/Main  
Paul-Ehrlich-Str. 40  
D-60596 Frankfurt/Main  
[K.Hunfeld@em.uni-frankfurt.de](mailto:K.Hunfeld@em.uni-frankfurt.de)

Copyright Shaker Verlag 2004

All rights reserved. No part of this publication may be reproduced, stored in a  
retrieval system, or transmitted, in any form or by any means, electronic,  
mechanical, photocopying, recording or otherwise, without the prior permission  
of the publishers.

Printed in Germany.

ISBN 3-8322-3347-4  
ISSN 1614-7758

Shaker Verlag GmbH • P.O. BOX 101818 • D-52018 Aachen  
Phone: 0049/2407/9596-0 • Telefax: 0049/2407/9596-9  
Internet: [www.shaker.de](http://www.shaker.de) • eMail: [info@shaker.de](mailto:info@shaker.de)

*For my beloved wife and my children*



		Page
<b>A.</b>	<b>Introduction</b>	<b>1</b>
A.1.	Emergence of tick-transmitted diseases	1
A.1.1.	<i>Borrelia</i> , <i>Ehrlichia</i> , and <i>Babesia</i> : Pathogens of increasing medical relevance in Europe	3
A.2.	<i>B. burgdorferi</i> : the causative pathogen of Lyme disease (LD)	5
A.2.1	Taxonomy, genetic diversity, and microbiologic properties of <i>B. burgdorferi</i>	5
A.2.2.	Epidemiology of LD in Europe	8
A.2.3.	Clinical manifestations	11
A.2.4.	Microbiological diagnosis	15
A.2.5.	Treatment and antimicrobial susceptibility patterns	22
A.3.	Granulocytic <i>Ehrlichia</i> spp. the causative pathogens of Human Granulocytic Ehrlichiosis (HGE)	25
A.3.1.	Taxonomy, genetic diversity, and microbiologic properties of <i>Ehrlichia</i> spp.	25
A.3.2.	Epidemiology	27
A.3.3.	Clinical manifestations	29
A.3.4.	Microbiological diagnosis	31
A.3.5.	Treatment options and antimicrobial susceptibility pattern	33
A.4.	<i>B. microti</i> and <i>B. divergens</i> : the causative pathogens of human babesiosis	34
A.4.1.	Taxonomy, genetic diversity, and microbiologic properties of the genus <i>Babesia</i>	34
A.4.2.	Epidemiology	36
A.4.3.	Clinical disease manifestation	37
A.4.4.	Microbiological diagnosis	39
A.4.5.	Treatment and antimicrobial susceptibility patterns	41
A.5.	Aims of the investigations summarised in this thesis	42

		Page
<b>B.</b>	<b>Results</b>	<b>43</b>
B.1.	Molecular characterisation of tick-borne microorganisms	43
B.1.1	<i>B. burgdorferi</i> isolates	43
B.1.2.	<i>E. phagocytophila</i> isolates	46
B.1.3.	<i>B. microti</i> and <i>B. divergens</i> isolates	47
B.2.	Evaluation of serological assays used for seroepidemiological investigations and the laboratory diagnosis of human LD, ehrlichiosis, and babesiosis	48
B.2.1.	Evaluation of a newly-developed recombinant ELISA (RE) for the detection of anti- <i>B. burgdorferi</i> IgG- and IgM-antibodies	48
B.2.1.1.	Test sensitivity	49
B.2.1.2.	Test specificity	49
B.2.1.3.	Comparison with an established whole cell ELISA	50
B.2.1.4.	Test performance	52
B.2.2.	Systematic evaluation of diagnostic quality of LD serology: Results from the German proficiency testing program 1999-2001	52
B.2.2.1.	Participating laboratories	52
B.2.2.2.	Applied test systems	53
B.2.2.3.	Accuracy of test results	54
B.2.2.4.	False positive and false negative test results and evaluation of test kit quality	62
B.2.3.	Evaluation of and seroepidemiological investigations with a diagnostic IFA for the detection of IgG- and IgM-antibodies against <i>E. phagocytophila</i> .	64
B.2.3.1.	Determination of cut-off titers and evaluation of test specificity	64

	<b>Page</b>
B.2.3.2. Seroprevalence of antibodies against <i>E. phagocytophila</i> in patients with LD	66
B.2.3.3. Seropositive individuals without symptoms of active LD	67
B.2.3.4. Statistical analysis	67
B.2.3.5. Incidence and prevalence of <i>E. phagocytophila</i> in young healthy German subjects	67
B.2.4. Evaluation of and seroepidemiological investigations with a diagnostic IFA for the detection of antibodies against <i>B. microti</i> and <i>B. divergens</i>	69
B.2.4.1. Determination of cut-off titers and evaluation of test specificity	69
B.2.4.2. Seroprevalence of <i>B. microti</i> and <i>B. divergens</i> antibodies in tick-exposed individuals and healthy controls	74
B.2.4.2.1. Patients with EM	74
B.2.4.2.2. Individuals with positive borreliosis serology but lacking clinical symptoms of active LD	74
B.2.4.2.3. Patients with a history of tick bite	74
B.2.4.2.4. Statistical analysis	76
B.3. Investigations of the biological activity of antibody-containing immune sera against <i>B. burgdorferi</i> : A promising approach for the development of a new class of diagnostic tests	77
B.3.1. Comparison of two laboratory methods for the determination of serum resistance in <i>B. burgdorferi</i> isolates	77
B.3.1.1. Serum sensitivity among borrelial isolates to NHS	77
B.3.1.2. Deposition of C6 and C9 on borrelial surfaces	80
B.3.2. Borreliacidal activity of early LD sera against complement-resistant <i>B. afzelii</i> FEM1 wild type and an OspC-lacking variant	81

	<b>Page</b>
B.3.2.1.	82
B.3.2.2.	83
B.3.2.3.	85
B.3.2.4.	88
B.4.	91
B.4.1	91
B.4.1.1.	91
B.4.1.2.	93
B.4.2.	94
B.4.2.1.	94
B.4.2.2.	97
B.4.2.3.	101
B.4.2.4.	104
B.4.2.5.	106
B.4.2.6.	108
B.4.2.7.	111
B.5.	116
B.5.1.	116



	<b>Page</b>
B.5.1.1. Time-kill studies performed on <i>B. burgdorferi</i> exposed to erythromycin, telithromycin, and cethromycin	116
B.5.1.2. Time-kill studies performed on <i>B. burgdorferi</i> exposed to ciprofloxacin and gemifloxacin	118
B.5.2. Electron microscope analysis of <i>B. burgdorferi</i> exposed to increasing concentrations of newly-developed antimicrobial agents	120
B.5.2.1. Electron microscope analysis of <i>B. burgdorferi</i> exposed to cethromycin	120
B.5.2.2. Electron microscope analysis of <i>B. burgdorferi</i> exposed to ciprofloxacin and gemifloxacin	122
B.5.3. Differential protein expression of <i>B. burgdorferi</i> exposed to increasing concentrations of penicillin G and doxycycline	124
B.5.3.1. MIC determination	125
B.5.3.2. Identification of proteins with variable expression after exposure of Borreliae to increasing concentrations of penicillin G and doxycycline	125
B.6. <i>In vitro</i> susceptibility testing of <i>E. phagocytophila</i> against well-known and newly developed antimicrobial agents	129
B.6.1. Evaluation of a new semiquantitative PCR-based microdilution method for <i>in vitro</i> susceptibility testing of <i>E. phagocytophila</i> against antimicrobial substances	129
B.6.1.1. Precision and reproducibility of semiquantitative measurement of ehrlichial growth by LightCycler <i>16S-rDNA</i> PCR	129
B.6.1.2. Test sensitivity	131
B.6.1.3. Test reproducibility and quality control	133
B.6.2. Characterisation of the <i>in vitro</i> susceptibility profile of <i>E. phagocytophila</i> against antimicrobial substances as determined by a LightCycler PCR-based microdilution test method under standardised conditions	135

		<b>Page</b>
<b>C.</b>	<b>Discussion</b>	
C.1.	Serodiagnosis of LD: Diagnostic problems related to the current lack of test standardisation	137
C.1.1.	External quality control of LD serology: The systematic approach of the German proficiency testing program	137
C.1.2.	Quality of LD serology in the routine microbiological laboratory: Lessons learned from the German proficiency testing program established in 1999	138
C.1.3.	Necessity of diagnostic standardisation: Future perspectives in promoting better test quality	140
C.2.	Recombinant test systems: A novel approach for a more accurate serological diagnosis of LD	141
C.3.	Tick- borne pathogens other than <i>B. burgdorferi</i> (TOBB): Continuing problems of epidemiology and microbiological diagnosis	144
C.3.1.	Contributions to the seroepidemiology and medical significance of <i>E. phagocytophila</i> in midwestern Germany	145
C.3.2.	Contributions to seroepidemiology and medical significance of <i>Babesia spp.</i> in midwestern Germany	148
C.4.	Sensitivity testing of <i>B. burgdorferi</i> to human serum by growth inhibitory assays: A new diagnostic approach to diagnosing active LD	151
C.4.1.	Evaluation of test procedures for the determination of serum resistance	151
C.4.2.	Evaluation of a GIA and an IFA for the determination of complement resistance of <i>B. burgdorferi</i> isolates	152
C.4.3.	Evaluation of laboratory tests for a better characterisation of the bactericidal immune response of human immune sera directed against <i>B. burgdorferi</i> isolates	154

	<b>Page</b>
C.5. Standardised <i>in vitro</i> susceptibility testing of <i>Borrelia burgdorferi</i> against well-known and newly-developed antimicrobial agents – Possible implications for new therapeutic approaches in LD	158
C.5.1. <i>In vitro</i> susceptibility determination of the <i>B. burgdorferi</i> complex against antimicrobial agents: Problems and drawbacks of current test methods	159
C.5.2. Interactions between antimicrobial agents and the test medium	161
C.5.3. Colorimetric microdilution <i>in vitro</i> susceptibility testing: A novel approach to MIC determination of antimicrobial agents against <i>B. burgdorferi</i>	162
C.5.4. Characterisation of borreliacidal activity of antimicrobial agents <i>in vitro</i> using time-kill experiments	163
C.5.5. Determination of MBCs: A more restrictive tool for characterising borreliacidal activity	164
C.5.6. <i>In vitro</i> testing of <i>B. burgdorferi</i> against well known and recently introduced antimicrobial agents applying a standardised methodology	165
C.5.7. Possible heterogeneity of different genospecies of the <i>B. burgdorferi</i> complex with regard to their <i>in vitro</i> susceptibility pattern	168
C.5.8. Current problems of treatment in LD: Treatment failure, re-infection, misdiagnosis, and co-infection	169
C.6. Changes in the protein expression pattern of borreliae exposed to antimicrobial agents: Evidence for possible escape mechanisms on the part of the pathogen?	171
C.7. Recently-introduced antimicrobial agents: Possible implications for alternative therapeutic approaches in LD and other tick-borne diseases?	174
C.7.1. <i>In vitro</i> effectiveness of new fluoroquinolones against <i>B. burgdorferi</i>	174
C.7.2. <i>In vitro</i> effectiveness of new ketolides against <i>B. burgdorferi</i>	177
C.7.3. <i>In vitro</i> susceptibility testing of <i>E. phagocytophila</i> against well-known and recently-introduced antimicrobial agents by use of a new semiquantitative PCR- based testing method developed for fastidious organisms	181

	<b>Page</b>
C.7.4. New therapeutic strategies in the treatment of tick-borne diseases: Need for <i>in vivo</i> studies	184
<b>D. Materials and Methods</b>	<b>187</b>
D.1. Materials and microorganisms	187
D.1.1. Bacterial strains	187
D.1.1.1. <i>B. burgdorferi</i> isolates	187
D.1.1.2. <i>E. phagocytophila</i> isolates	187
D.1.1.3. <i>Babesia</i> spp. isolates	187
D.1.1.4. Reference strains	188
D.1.2. Culture media	188
D.1.2.1. Modified Barbour-Stoenner-Kelly (BSK)-medium for culturing <i>B. burgdorferi</i>	188
D.1.2.2. Cell-line and culture media used for the propagation of <i>E. phagocytophila</i>	189
D.1.2.3. HL-60 cell line	189
D.1.2.4. Cell culture medium for the propagation of HL60 cells	189
D.1.2.5. Cell culture medium for the propagation of HL60 cells infected with <i>E. phagocytophila</i> .	189
D.1.3. Oligonucleotides and antibodies	190
D.1.3.1. Oligonucleotides	190
D.1.3.2. Antibodies	192
D.1.4. Serum sources and patient samples used for the evaluation of serological diagnostic assay systems	192
D.1.4.1. Serum samples used for the evaluation of a recombinant ELISA (RE)	192
D.1.4.2. Sera used throughout the German LD proficiency testing program 1999 - 2001	193
D.1.4.3. Serum samples used for seroepidemiological investigations of anti- <i>E. phagocytophila</i> antibody prevalence in western Germany	193

	<b>Page</b>
D.1.4.4. Serum samples used for seroepidemiological investigations of anti- <i>Babesia</i> spp. antibody prevalence in midwestern Germany	194
D.1.4.5. Other sera used for immunological experiments	195
D.1.4.5.1. Immune sera from LD patients	195
D.1.4.5.2. Sources of Non-immune Human Serum (NHS)	195
D.2. Methods	195
D.2.1. Culture methods	195
D.2.1.1. Culture and propagation of borrelial isolates	195
D.2.1.2. Culture and propagation of HL60 cell line and ehrlichial isolates	196
D.2.1.2.1. Culture and propagation stock cultures of HL60 cells	196
D.2.1.2.2. Propagation of <i>E. phagocytophila</i> isolates	196
D.2.2. Molecular microbiological methods	197
D.2.2.1. Polymerase chain reaction (PCR) methods	197
D.2.2.1.1. PCR for the detection of borrelial gens	197
D.2.2.1.2. RFLP-analysis of 5S-23S “intergenic spacer”-region of <i>B. burgdorferi</i>	197
D.2.2.1.3. Reverse transcription polymerase chain reaction (RT-PCR) for the detection of flagellin, OspA, and OspC mRNA	197
D.2.2.1.4. <i>16S-rRNA</i> -gene PCR for the universal detection and characterisation of bacterial pathogens	198
D.2.2.1.5. PCR for the detection of <i>epank</i> gene fragments of <i>E. phagocytophila</i>	198
D.2.2.1.6. PCR for the detection of a species-specific region of the <i>18S-rRNA</i> gene of <i>B. microti</i>	199
D.2.2.1.7. PCR for the detection of a genus- specific region of the <i>18S-rRNA</i> gene of <i>Babesia</i> spp.	199
D.2.2.2. Sequencing of PCR-Products	200
D.2.2.3. Restriction analysis using DNA restriction endonucleases	200
D.2.3. Organisation and structure of the German LD proficiency testing Program	200

	<b>Page</b>
D.2.3.1. Preparation and shipment of serum samples	201
D.2.3.2. Assessment of correct test results by reference laboratories	201
D.2.3.3. Study conditions and statistical analysis	202
D.2.4. Serological assays and test procedures	203
D.2.4.1. Development and evaluation of an ELISA (RE) using recombinant proteins for the serological diagnosis of LD	203
D.2.4.1.1. Preparation of the assay system	203
D.2.4.1.2. Test procedure	203
D.2.4.1.3. Prospective evaluation of the RE in comparison to a conventional whole-cell lysate ELISA	204
D.2.4.2. Other commercial ELISA-tests used for serological testing for LD.	204
D.2.4.3. Recombinant immunoblot for serodiagnosis of LD	204
D.2.4.4. Whole-cell lysate <i>B. burgdorferi</i> immunoblot for the serodiagnosis of LD	205
D.2.4.5. IFA for serological diagnosis of anti- <i>E. phagocytophila</i> IgG- and IgM-antibodies	205
D.2.4.6. IFAs for serological diagnosis of <i>B. microti</i> and <i>B. divergens</i> infection	205
D.2.4.6.1. IFA for serological diagnosis of <i>B. microti</i> infection	205
D.2.4.6.2. IFA for serological diagnosis of <i>B. divergens</i> infection	205
D.2.4.6.3. Serological testing for anti- <i>Babesia</i> spp. IgM- and IgG- antibodies	206
D.2.5. Serobiological and protein analytical assays	206
D.2.5.1. <i>In vitro</i> borreliar growth inhibition assay (GIA)	206
D.2.5.2. Determination of total complement activity (CH <sub>50</sub> )	207
D.2.5.3. Determination of protein concentrations	207
D.2.6. Immune biological detection of borreliar antigens and complement components	207
D.2.6.1. Detection of deposited C6 and C9 (TCC)	207
D.2.6.2. Detection of deposited complement components on the surfaces of borreliae by IFA	208

	<b>Page</b>
D.2.7. Gel electrophoretic methods and immunoblotting of proteins	208
D.2.7.1. Gel electrophoresis of borrelial proteins	208
D.2.7.2. Immunoblotting of proteins	208
D.2.7.3. Immunoblot analysis of immune sera	209
D.2.8. Isolation of borrelial outer membrane fractions	209
D.2.9. <i>In vitro</i> antimicrobial susceptibility testing of <i>B. burgdorferi</i> and <i>E. phagocytophila</i> against antimicrobial agents	210
D.2.9.1. Antimicrobial drugs and microdilution trays	210
D.2.9.2. Broth microdilution susceptibility testing of <i>B. burgdorferi</i>	210
D.2.9.2.1. Quality control experiments	210
D.2.9.2.2. Determination of test sensitivity	210
D.2.9.2.3. Determination of minimal inhibitory concentration (MIC)	211
D.2.9.2.4. Determination of minimal borreliacidal concentration (MBC)	211
D.2.9.2.5. Time-kill studies	211
D.2.9.3. <i>In vitro</i> susceptibility testing of <i>E. phagocytophila</i>	212
D.2.9.3.1. Broth microdilution susceptibility testing	212
D.2.9.3.2. Detection of ehrlichial growth by semiquantitative PCR	212
D.2.9.3.3. Statistical methods for the determination of bacterial growth as measured by semiquantitative PCR	215
D.2.9.3.4. Preparation of an internal quantitative DNA standard for <i>E. phagocytophila</i>	217
D.2.9.3.5. Determination of growth kinetics for both tested isolates of <i>E. phagocytophila</i>	217
D.2.9.3.6. Determination of MIC	217
D.2.9.3.7. Quality control experiments	217
D.2.10. Electron microscope analysis of <i>B. burgdorferi</i> isolates exposed to antimicrobial agents	218

---

	<b>Page</b>
D.2.11. Analysis of antibiotic-exposed borreliae by two dimensional protein electrophoresis (2-DE) and matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry (MALDI-TOF-MS)	218
D.2.11.1. Broth micro- and macrodilution susceptibility testing of borrelial cells	218
D.2.11.2. Preparation of protein samples	219
D.2.11.3. Two dimensional electrophoresis (2-DE) and staining conditions	219
D.2.11.4. Scanning and spot detection	219
D.2.11.5. Identification of proteins by MALDI-TOF-MS	220
D.2.12. Statistics	220
<b>E. Summary and conclusion</b>	<b>221</b>
<b>F. References</b>	<b>225</b>
<b>G. List of abbreviations</b>	<b>255</b>